Clinical Trials

266 enrolled

Nasopharyngeal Carcinoma

NCT06239727 2026-03-06

Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response

593 enrolled

Nasopharyngeal Carcinoma

NCT06632327 2026-03-04

Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

1,100 enrolled

Lung Neoplasms

NCT07000084 2026-03-04

GAIN-BCG

330 enrolled

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT07436741 2026-02-27

Surufatinib Plus Gemcitabine and Nab-paclitaxel vs. Gemcitabine Plus Nab-paclitaxel in Neoadjuvant Therapy for High - Risk Resectable or Borderline Resectable Pancreatic Cancer

106 enrolled

Pancreatic cancer, adult

NCT07385079 2026-02-03

Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma

412 enrolled

Nasopharyngeal Neoplasms

NCT06958328 2026-02-02

LAP100

356 enrolled

Pancreatic Neoplasms

NCT07097142 2026-02-02

Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study

486 enrolled

Urinary Bladder Neoplasms

NCT07373990 2026-01-28

Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma

418 enrolled

Nasopharyngeal Neoplasms

NCT04722978 2025-12-17

Standard Chemotherapy Plus Moxifloxacin as First-line Treatment for Metastatic Triple-negative Breast Cancer

228 enrolled

Triple Negative Breast Neoplasms

NCT06908993 2025-12-17

COMET

133 enrolled

Carcinoma, Non-Small-Cell Lung

NCT07272109 2025-12-15

PTCA199-16

210 enrolled

Pancreatic Neoplasms

NCT07088263 2025-12-11

Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer

192 enrolled

Breast Neoplasms

NCT06929286 2025-10-30

A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)

125 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT02514681 2025-09-10

PRECIOUS

226 enrolled

Breast Neoplasms

NCT07155629 2025-09-04

LEFT-PANC

381 enrolled

Pancreatic Cancer Resectable

NCT06255392 2025-08-15

Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer

200 enrolled

Fludzoparib" and Anti-angiogenic

NCT06018883 2025-08-07

PTCA199-3

100 enrolled

Classical hematology

Anemia

NCT06250972 2025-08-07

PTCA199-11

210 enrolled

Pancreatic Adenocarcinoma

NCT04574960 2025-07-20

NAUTICAL

14 enrolled

Urinary Bladder Neoplasms

NCT04907370 2025-07-16

DIAMOND

532 enrolled

Nasopharyngeal Carcinoma

NCT07062263 2025-07-14

TAB-2

220 enrolled

Biliary Tract Neoplasms

NCT03750669 2025-05-13

Sequential Use of AG and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer

324 enrolled

Pancreatic Neoplasms

NCT05342194 2025-04-23

Toripalimab Plus Lenvatinib and Gemcitabine-based Chemotherapy in 1L Treatment of Advanced ICC: a Phase III Study

480 enrolled

Cholangiocarcinoma

NCT05615818 2025-04-23

SAFIR-ABC10

800 enrolled

Biliary Tract Neoplasms

NCT02170090 2025-03-30

ACTICCA-1

789 enrolled

Gallbladder Neoplasms, Cholangiocarcinoma

NCT00446225 2025-03-05

EURTAC

174 enrolled 20 charts

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT06170489 2025-02-28

A Phase III Clinical Study Comparing JS004 Plus Toripalimab With Investigator-Selected Chemotherapy in Patients With PD-(L)1monoclonal Antibody Refractory Classic Hodgkin Lymphoma (cHL)

185 enrolled

Lymphoid

Hodgkin Disease

NCT05587374 2025-01-23

GEMSTONE

490 enrolled

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

NCT03840421 2025-01-13

GP Vs PF As Induction Chemotherapy Combined with CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma

468 enrolled

Nasopharyngeal Carcinoma, Head and Neck Neoplasms, Nasopharyngeal Diseases, Nasopharyngeal Neoplasms

NCT02460887 2024-12-03

The Role of Induction Gemcitabine and Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma in the Era of IMRT

236 enrolled

Nasopharyngeal Carcinoma

NCT03673072 2024-11-12

GAIN

68 enrolled

Biliary Tract Neoplasms

NCT03598270 2024-08-30

ANITA

417 enrolled

Gynecologic

Ovarian Neoplasms

NCT05979961 2024-08-06

Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma

454 enrolled

Nasopharyngeal Carcinoma

NCT05764044 2024-07-30

AddChemo

365 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT04557020 2024-05-01

Adding PD-1 Inhibitor to Neoadjuvant and Adjuvant for NPC

Phase 3 Unknown

200 enrolled

Nasopharyngeal Carcinoma

NCT01827553 2024-04-11

CONKO-007

830 enrolled

Pancreatic Neoplasms

NCT02395016 2024-04-04

A Study of Nimotuzumab Combinated With Gemcitabine in K-RAS Wild-type Locally Advanced and Metastatic Pancreatic Cancer

90 enrolled 18 charts

Pancreatic Neoplasms

NCT06327932 2024-03-25

HIVEC in Patients With Non-Muscle-Invasive Bladder Cancer

320 enrolled

Non-Muscle Invasive Bladder Neoplasms

NCT06268652 2024-02-20

Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer

302 enrolled

Breast Neoplasms

NCT05189028 2024-02-06

Study of Neoadjuvant Chemotherapy Versus Definite Concurrent Chemoradiotherapy for Locally Advanced Bulk Cervical Cancer

Phase 3 Unknown

290 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT00617656 2024-01-30

BREC

Phase 3 Terminated

382 enrolled 15 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06217042 2024-01-22

HR070803 in Combination With Oxaliplatin, 5-fluorouracil/LV Versus GX as Adjuvant Therapy for Pancreatic Cancer

524 enrolled

Pancreatic Neoplasms

NCT02539537 2024-01-09

NEOPAN

171 enrolled

Carcinoma, Pancreatic Neoplasms

NCT06017284 2023-11-24

PTCA199-5

100 enrolled

Nausea, Pancreatic Neoplasms, Vomiting

NCT06026878 2023-09-07

GNT Induction Treatment in Locally Advanced NPC

228 enrolled

Nasopharyngeal Carcinoma

NCT00128310 2023-05-31

Vinorelbine Versus Gemcitabine Plus Vinorelbine in Metastatic Breast Cancer Patients

252 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT05854849 2023-05-11

Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC

244 enrolled

Nasopharyngeal Carcinoma, Neoplasm Metastasis

NCT05527470 2023-05-03

Induction Chemotherapy Followed by IMRT or Concurrent Chemoradiotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma

440 enrolled